BRAF Gene Variant in Papillary Carcinoma of Thyroid: A Single Institution study from Karnataka

Volume 20 No 10 (2022)

Dr Ashwini B R , Dr Himani Gupta , Dr Ankita Pai , Dr Mamatha R , Dr M Natarajan , Dr Dayananda S Biligi

DOI: 10.14704/nq.2022.20.10.NQ55002

Abstract

Thyroid cancer is the most common malignancy of endocrine system with Papillary thyroid carcinoma (PTC) as the commonest malignancy. One of the commonest genetic alterations seen in PTC is BRAF mutation. BRAF is a proto-oncogene and a part of RAS/MAPKinase pathway. Among the BRAF mutations, the V600E alteration is the most commonly reported mutation. There are differences about the prevalence of BRAFV600E mutation in PTCs in different regions, which is said to vary between 25 to 86%. There is no data from Karnataka about the incidence of BRAF V600E mutation and its phenotypic presentation.

Keywords

Papillary carcinoma of thyroid, BRAF V600E mutation, DNA Sequencing, larger tumor size

Copyright © Neuroquantology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the Neuroquantology are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJECSE right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.